Tables for predicting a child's final height from her present height and bone age were published by Bayley (1946) , and in their revised form (Bayley and Pinneau, 1952) for use with the bone age atlas of Greulich and Pyle (1959) are widely used for clinical purposes today. These tables have the apparent disadvantage that they do not allow the exact bone age to be taken into account but use only information as to whether it is average, advanced by 1 year, or delayed by 1 year. Also, the Atlas method of assessing bone age has certain theoretical disadvantages which are discussed by Tanner et al. (1975b) Roche and Wettenhall (1969) suggests that the Bayley and Pinneau method has about the same accuracy in tall girls as in shorter ones and this is probably true also of the TW2 method. Neither method is valid when applied to girls whose tallness is of pathological origin.
Treatment
The management of those pathological states which may be associated with tallness will not be considered here. When active treatment is possible it must be aimed at the underlying disorder.
Let us assume that we are faced with a perfectly healthy 10-year-old girl whose predicted adult height is 5 feet 11 inches (180 cm). If we allow for errors of prediction, she might reach 6 feet (183 cm) or even 6 feet 1 inch (185 cm). On the other hand, she might only reach 5 feet 9 inches (175 cm). If we repeat the prediction two or three times at 6-monthly intervals we may be able to make a subjective judgement as to whether the initial error was on the high or the low side, but we shall still be uncertain about the outcome.
If we were able to offer a simple and absolutely safe treatment which could be guaranteed to reduce the final height by 2 or 3 inches, the parents would probably wish us to use it. Unfortunately, we are not in this happy position. The only active treatments we can offer are oestrogens and surgery.
Oestrogens may accelerate the maturation of the skeleton and thereby reduce the time for which growth can continue. In some cases they may also reduce the speed of growth. The exact mechanism of oestrogen action is not clear. They do not reduce the rate of growth hormone production but apparently enhance it (Plotnick et al., 1974) , and high blood levels of growth hormone have been found in tall girls under treatment though the somatomedin levels were low. Weidemann and Schwartz (1972) have also shown suppression of somatomedin by oestrogen. This action would explain reduction in growth velocity by oestrogens but not the concurrent acceleration of skeletal maturation, which implies an androgenic effect. Zachmann et al. (1975) have suggested that the large doses of oestrogen used for the treatment of tall girls may act on the skeleton indirectly by increasing the output of androgens from the adrenals. They have reported a mean reduction in adult height (as compared with TW2 prediction) of 4 6 cm in 40 girls, though no difference between final and predicted height was found in 3 of these patients. They gave ethinyl estradiol 0 3 mg daily to 29 of these cases, with norethisterone 10 mg daily for 5 to 7 days every fourth week. The remaining 11 cases were treated with stilboestrol 3 mg daily. The mean duration of treatment was 1 * 7 years.
Several other authors using various oestrogen preparations have reported reduction in final height similar to or less than this, when compared with the predicted height before treatment. Thus, we can offer treatment to our patient which is easy to take and which may lead to her final height being up to 2j inches (6 cm) less than our prediction but may have no apparent effect at all. We cannot say that it is absolutely safe.
The association between oral contraceptives and thromboembolism is well known, though it has not been observed in girls treated with oestrogen to reduce their stature. Hypertension and liver damage are other possible side effects, and we do not know whether or not some impairment of fertility may result. Some girls have become pregnant after treatment but the majority of treated subjects are not yet married. Theoretically the risks are considerable but it appears that they seldom materialize.
Clearly the balance between 'pros' and 'cons' of oestrogen therapy is a fine one, and treatment should not be undertaken unless the parents fully understand all the implications and are convinced that the risks are outweighed by the threat to their child's future happiness if nothing is done. The author is seldom prepared to offer treatment even on these terms unless serial predictions indicate that the patient's final stature may exceed 6 feet (183 cm). However, one cannot make absolute rules.
Ethinyl oestradiol as used by Zachmann et al. is probably the most satisfactory regimen, though a lower dosage may be equally effective. Conjugated oestrogens contain substances of unknown effect, while stilboestrol sometimes causes unsightly enlargement and pigementation of the areola. Oestradiol valerate is relatively free from side effects but it must be given by injection.
It is reasonable to expect the effect of the treatment to diminish when it is begun at later ages. Hence, we could recommend that it should begin at the earliest age when growth of the breasts would be acceptable. However, the results of Zachmann et al. suggest that the age at which treatment begins may not greatly affect the results and that treatment even after menarche may be effective. These authors suggest that there may be psychological advantages in delaying treatment until the natural development of the breasts has begun. However, it should be remembered that we never know exactly how effective the treatment has been in an individual case and can only refer to our prediction with its inherent error.
The alternative treatment, by surgical shortening of the limbs, is clearly a greater immediate stress for the patient than taking a daily oestrogen pill, but has the great advantage that it can be deferred until the patient's adult height is known and she has discovered whether or not it is a sufficient handicap to justify the procedure. If her legs are relatively long in relation to the trunk (as they frequently are in tall girls) the surgery need not result in any apparent disproportion. Orthopaedic surgeons differ in their attitude to this form of treatment and many would be unwilling to undertake it except in the most extreme circumstances.
Oestrogen therapy is justified in a small number of very tall girls who are so distressed by their growth prospects that a possibility of losing even an inch or two from their final height is a great comfort to them. It should only be undertaken after the fullest possible consultation with the parents and the child herself, and under the guidance of someone experienced in the assessment of growth. Perhaps in the future somatostatin may have a role in the treatment of these patients.
